In a large-scale meta-analysis, it has been recently shown that the transcription factor 4 (TCF4) gene is among the most prominent susceptibility genes for schizophrenia. Moreover, transgenic mice overexpressing TCF4 in the brain display a reduction of sensorimotor gating measured by prepulse inhibition (PPI) of the acoustic startle response (ASR). PPI is heritable and has been established as an important translational endophenotype of schizophrenia. We therefore investigated the impact of the schizophrenia susceptibility gene TCF4 (rs9960767) on sensorimotor gating of the ASR in healthy humans and in patients with a schizophrenia spectrum disorder. We assessed PPI, startle reactivity, and habituation of the ASR in two independent samples. The first sample consisted of 107 healthy volunteers from London, UK. The second sample was a schizophrenia spectrum group (n ϭ 113) of 73 schizophrenia patients and 40 individuals at high risk for schizophrenia from Bonn, Germany (total sample n ϭ 220). In both samples, PPI was strongly decreased in carriers of the schizophrenia risk allele C of the TCF4 gene (meta-analysis across both samples: p ϭ 0.00002), whereas startle reactivity and habituation were unaffected by TCF4 genotype. Sensorimotor gating is modulated by TCF4 genotype, indicating an influential role of TCF4 gene variations in the development of early information-processing deficits in schizophrenia.
Introduction
Although schizophrenia is a strongly inherited disease with a heritability of 80% or more, the genetic basis of this disease is still elusive. A recent meta-analysis across SNP data from several large genomewide scans revealed that the risk of schizophrenia was significantly associated with a marker in intron four of the transcription factor 4 (TCF4 ) gene on chromosome 18q21.2 (Stefansson et al., 2009 ). Interestingly, a translational animal study recently showed that transgenic mice that moderately overexpress TCF4 postnatally in the brain display profound reductions in sensorimotor gating (Brzó zka et al., 2010) -an established translational and behavioral endophenotype of schizophrenia (Gottesman and Gould, 2003) . TCF4 is a class I basic helix-loophelix (bHLH) protein that is involved in the development of the mammalian CNS. Although TCF4 shows sustained expression in several brain regions throughout lifetime, its function in the adult CNS remains widely unclear (Soosaar et al., 1994; Flora et al., 2007) .
Sensorimotor gating is commonly operationalized by prepulse inhibition (PPI) of the acoustic startle response (ASR). PPI is defined as a substantial reduction of the startle amplitude that occurs when a distinctive nonstartling stimulus is presented 30 -500 ms before the startling stimulus (Graham, 1975) . PPI is regulated by a cortico-striato-pallido-pontine (CSPP) circuitry including frontal and mediotemporal regions, ventral striatum, ventral pallidum, and pontine regions of the brainstem (Fendt et al., 2001; Swerdlow et al., 2001 ). Several neuropsychiatric disorders present diminished PPI ), but this is most strongly evident in schizophrenia spectrum disorders (Braff et al., 1992; Cadenhead et al., 1993; Kumari et al., 2000; Parwani et al., 2000; Ludewig et al., 2003) . Furthermore, PPI is heritable (Anokhin et al., 2003; Greenwood et al., 2007) , reduced in unaffected relatives of schizophrenia patients (Cadenhead et al., 2000; Kumari et al., 2005a) , influenced by SNPs within the dopamine, acetylcholine, and serotonin system (Quednow et al., 2008b (Quednow et al., , 2009 Roussos et al., 2008a,b; Petrovsky et al., 2010) and already decreased during the prodromal stage of schizophrenia (Quednow et al., 2008a) , suggesting that PPI is an important and valid candidate as an intermediate or endophenotypic marker in genetic studies of schizophrenia (Gottesman and Gould, 2003) .
Based on the recent finding that the TCF4 SNP rs9960767 is a genetic risk factor for schizophrenia, that transgenic mice overexpressing TCF4 show reduced sensorimotor gating, and that sensorimotor gating is an established endophenotype of schizophrenia, we hypothesized that human carriers of the schizophrenia risk allele C of the TCF4 rs9960767 SNP would exhibit decreased sensorimotor gating. To avoid spurious results, we investigated two independent European Caucasian samples-a sample of 107 healthy volunteers recruited in United Kingdom, and a combined sample of 73 schizophrenia inpatients and 40 individuals at high risk for schizophrenia recruited in Germany, to directly test for replicability of our findings. This allowed us to explore the impact of this SNP in a sample of healthy subjects with a normal expression of the PPI endophenotype as well as in a schizophrenia spectrum sample with a known alteration of the endophenotype.
Materials and Methods
Participants. For the first sample, 107 healthy Caucasian volunteers (54 males, 53 females) with self-reported grandparents of European origin were recruited through local advertisements in South London, United Kingdom. Participants aged between 18 and 45 years were screened for the exclusion criteria of DSM-IV Axis I disorders using the Structured Clinical Interview for DSM-IV Disorders for healthy subjects (SCID-NP). Additional exclusion criteria were a history of head injuries, any known neurological abnormalities or systemic illness with known neurological complication, a first-degree relative with psychosis or obsessive-compulsive disorder, and a history of substance abuse or dependence. Current smoking behavior was assessed with the Fagerström Test for Nicotine Dependence (Heatherton et al., 1991) and the number of cigarettes smoked per day (CPD).
For the second sample, 73 inpatients (50 males, 23 females) admitted to the psychiatric hospital of the University of Bonn, Germany, with a diagnosis of schizophrenia according to DSM-IV were included. Moreover, 40 subjects with symptoms indicating high risk for schizophrenia (23 males, 17 females) were recruited as described in detail previously (Häfner et al., 2004; Quednow et al., 2008a; Frommann et al., 2010) . Patients and high-risk individuals were included if they were of Caucasian ethnicity with self-reported grandparents of European origin and aged between 18 and 65 years. Exclusion criteria were a history of head injuries, a neurological disease, a history of substance abuse or dependency, or a severe somatic disease. Every participant was evaluated with the Structured Clinical Interview (SCID-I). Clinical symptoms were measured with the Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1992) . Fourteen schizophrenia patients were never medicated (these patients experienced a first episode of psychosis), 12 patients received a typical antipsychotic, 43 patients were treated with an atypical antipsychotic, 3 received two atypical drugs, and 1 received a typical and an atypical antipsychotic. Four high-risk individuals received treatment with atypical antipsychotics. From schizophrenia patients, urine toxicologies were obtained before inclusion to rule out active substance abuse. The total (healthy and schizophrenia spectrum) sample consists of 220 individuals. For both samples, ethical approvals of the local ethics committees were obtained, and all participants provided written informed consent before inclusion.
Genotyping. In the healthy volunteers from London, DNA concentration from cheek swabs or from EDTA acid anticoagulated blood was adjusted using the PicoGreen quantitation reagent (Invitrogen) and 1 ng was genotyped using the iPLEX assay on the MassARRAY MALDI-TOF mass spectrometer (SEQUENOM). Genotyping was successful in 93.5% of subjects. To check for genotyping errors, CEU families were genotyped too with a 100% concordance rate. Furthermore, genotype frequency of the TCF4 rs9960767 SNP in the London sample (AA: 87.8%, AC: 10.2%, CC: 2%; A-allele: 92.9%, C-allele: 7.1%) was very similar as in the HapMap-CEU population available at the NCBI website (AA: 88.3%, AC: 10.0%, CC: 1.7%; A-allele: 93.3.%, C-allele: 6.7%; www.hapmap. org) and distributed in accordance with the Hardy-Weinberg Equilibrium (HWE) ( p ϭ 0.07).
In the German schizophrenia patients and high-risk individuals, DNA for genotyping was isolated either from EDTA acid anticoagulated blood or permanent cell cultures received after transforming the lymphocytes with Epstein-Barr virus. The isolation of the DNA followed the QIAGEN protocol for the Blood & Cell Culture DNA Maxi Kit (QIAGEN). PCR was performed using 12.5 ng of DNA. The TCF4 SNP (rs9960767) was analyzed by a TaqMan assay (Applied Biosystems). Genotyping was successful in 97.3% of subjects. For quality control, the complete sample was genotyped twice. Concordance among duplicate samples was 100%. Genotype frequency of the TCF4 SNP in the Bonn sample (AA: 89.5%, AC: 10.5%, CC: 0%; A-allele: 94.8%, C-allele: 5.2%) was also comparable to the HapMap-CEU population (see above) and as well distributed in accordance with HWE ( p ϭ 1.0).
Startle response measurement. The two samples were assessed with the same hardware but with slightly different PPI paradigms. In the London sample, we used three stimulus onset asynchronies (SOAs) of 30, 60, and 120 ms between the prepulse and the pulse alone (PA), while we used only a single SOA condition in the Bonn sample (120 ms). Equipment, setup, PPI testing, and data acquisition and scoring procedures for both methods have previously been described in detail [London sample: Kumari et al. (2005b) ; Bonn sample: Quednow et al. (2006a Quednow et al. ( ,b, 2008a ]. In both centers, we used the SRRED2 software (San Diego Instruments) to analyze the startle data. According to Braff et al. (1992) , the latency to startle response onset was defined by a shift of six digital units from the baseline value occurring between 21 and 120 ms after the acoustic startle stimulus. Latency to response peak was defined as the point of maximal amplitude that occurred within 150 ms after the startle stimulus. Response rejections were made in case of onset-to-peak latencies Ͼ95 ms, onset latencies Ͼ100 ms, and baseline shifts Ͼ90 digital units (e.g., due to spontaneous or voluntary blinks). Subjects with response rejections Ͼ50% were excluded from data analysis (healthy subjects: n ϭ 2; schizophrenia patients: n ϭ 3; high-risk individuals: n ϭ 2). All remaining subjects showed a mean startle amplitude Ͼ25 units-the commonly used threshold for analyzable startle data (Braff et al., 1992) .
The mean percentage PPI of startle amplitude was calculated using the following formula: %PPI ϭ 100 ϫ (amplitude on PA trials Ϫ amplitude on prepulse trials)/amplitude on PA trials (Braff et al., 1992) . For the assessment of startle habituation, PA trials were each divided into four blocks in the British sample and in six blocks in the German sample. The calculation of the habituation measures (early and late habituation in percentage, and linear gradient coefficient b) has been described in detail previously (Quednow et al., 2006a,b) . Startle reactivity was assessed by the mean amplitude of the first block of PA trials and the mean amplitude of all PA trials.
Statistical analysis. Given that the minor allele frequency of the TCF4 rs9960767 SNP is relatively low (ϳ6%) (Stefansson et al., 2009) , we compared only homozygous carriers of the A-allele with carriers of the schizophrenia risk allele C (AA vs AC ϩ CC). All demographic data were analyzed by ANOVA with the exception of frequency data. Frequency data were analyzed using Fishers exact 2 test. Given that sex, smoking, and antipsychotic medication might affect PPI (Swerdlow et al., 1997; Kumari and Gray, 1999; Swerdlow et al., 2006) , these variables were introduced as covariates in analyses of covariance (ANCOVA) of PPI data independent of the statistical significance of the covariates. All other psychophysiological parameters were analyzed with ANOVA. The confirmatory statistical comparisons were performed at a significance level set at p Ͻ 0.05 (two-tailed). Within the Pearson product-moment correlation analyses, the significance level was set at p Ͻ 0.01 (two-tailed) to avoid accumulation of ␣-error. Effect size calculations between two groups refer to Cohen's d. For meta-analysis of the genotype effects on PPI across both samples, we used Stouffer's z-trend method and Fisher's trend to combine p values (Whitlock, 2005) , and the weighted integration method as well as a random-effects model according to Hedges and Olkin to combine effect sizes (Hedges and Olkin, 1985 ); Armitage's trend test was used to analyze associations between the TCF4 SNP and schizophrenia (Armitage, 1955) .
Results

London sample (healthy volunteers)
The two genotype groups (homozygous AA-carriers vs C-allele carriers) did not differ regarding age, sex, years of education (YoE), habituation, and startle reactivity (Table 1) . However, there was not a single smoker in the C-allele group and, therefore, we compared the C-allele group with nonsmoking homozygous AA-carriers in additional analyses (see below).
PPI was strongly affected by TCF4 genotype: carriers of the schizophrenia risk allele C display decreased PPI levels (Table 1 , Fig. 1 A) . A 3 ϫ 2 (SOA condition ϫ genotype) repeatedmeasures ANCOVA with sex and CPD as covariates revealed significant main effects for the factors SOA condition (F (2,188) ϭ 11.4, p Ͻ 0.001, p 2 ϭ 0.11), sex (F (1,94) ϭ 7.5, p Ͻ 0.01, p 2 ϭ 0.07), and genotype (F (2,94) ϭ 11.2, p Ͻ 0.001, p 2 ϭ 0.11). Moreover, there was a significant interaction of the factors SOA and genotype (F (2,188) 14.5, p Ͻ 0.001, p 2 ϭ 0.14). The main effect of SOA reflects the well known nature of PPI to increase with rising SOA from 30 ms through 120 ms (Blumenthal, 1999) . The effect of sex reflects the known fact that women have generally lower PPI levels than men (pooled SOA conditions: F (1,103) ϭ 10.8, p Ͻ 0.001, p 2 ϭ 0.10) (Swerdlow et al., 1997) .
To exclude a potential impact of smoking on our results, we repeated the PPI analyses after exclusion of smokers (12 CC/AC carriers vs 63 AA carriers). However, PPI was still strongly affected by TCF4 genotype. A 3 ϫ 2 (SOA condition ϫ genotype) repeatedmeasures ANCOVA with sex as a covariate still revealed significant main effects for the factors SOA condition (F (2, 144) 
Bonn sample (schizophrenia patients and high-risk individuals)
The genotype groups did not differ regarding age, sex, smoking status, medication, and number of high-risk individuals (Table  2 ). There was a moderate effect of genotype on YoE (d ϭ 0.48), suggesting a possible effect of TCF4 genotype on intellectual functioning at least in schizophrenia patients and subjects at risk for schizophrenia (Table 2) .
The association between PPI and TCF4 genotype was confirmed in the Bonn sample. Again, carriers of the schizophrenia risk allele C revealed lower PPI levels ( Table 2 , Fig. 1 B) . An ANCOVA with sex, smoking status, and antipsychotic medication status as covariates revealed a significant main effect of genotype on PPI (F (1,100) ϭ 5.1, p Ͻ 0.05, p 2 ϭ 0.05). The influence of the covariate smoking status was not significant (F (1,100) ϭ 3.1, p ϭ 0.08, p 2 ϭ 0.03). Introduction of chlorpromazine equivalents as a covariate instead of medication status revealed a similar genotype effect (F (1,100) ϭ 4.6, p Ͻ 0.05, p 2 ϭ 0.05). Given that especially atypical antipsychotics could normalize PPI (e.g., Kumari et al., 2000) , we also excluded patients treated with atypical antipsychotics from analysis. Despite the limited power of the remaining sample (AA: n ϭ 55, CC ϩ AC: n ϭ 6), the genotype effect was still significant, while the effect size was improved (F (1,57) ϭ 4.11, p Ͻ 0.05, p 2 ϭ 0.07). Thus, medication effects could not explain our findings. Moreover, introduction of startle amplitude as a further covariate also did not change our results.
When the factor patient group (high-risk individuals vs schizophrenia patients) was introduced as a further fixed factor into the ANCOVA, the effect of genotype remained significant (F (1, 99) Due to the methodological differences, the Bonn schizophrenia spectrum sample and the London controls could not be directly compared regarding startle parameters and PPI. However, in line with many previous studies, the total group of schizophrenia patients and high-risk individuals revealed significantly decreased PPI levels when compared with an equivalent group of healthy controls [t (131) ϭ 2.8, p Ͻ 0.006, controls: 58.1% PPI (SEM 3.3), n ϭ 28], who were assessed in Bonn with the same PPI paradigm in a previous study (Quednow et al., 2008a) .
Meta-analysis of TCF4 genotype effect on PPI
To assess the total effect of TCF4 genotype on PPI across both samples, we applied several meta-analytic approaches (Table 3) . The significance level ranged between 0.0002 and 0.00002 depending on the method used. In general, meta-analytical methods combining effect sizes generated lower p values than methods combining p values. The mean effect size of the genotype effect on PPI was d ϭ 0.90.
Association between TCF4 genotype, PPI, and schizophrenia
To assess the association between the reduced PPI levels and TCF4 rs9960767 genotype, classical odds ratios were calculated (Bland and Altman, 2000) . If a clinical criterion of 1.0 SD is applied to define a low PPI level, reduced PPI shows a significant association with the schizophrenia risk allele of the TCF4 SNP within both samples (Table 4) . If a more conservative criterion of 1.5 SD is applied as a criterion for diminished PPI, previously significant associations within the London sample and the combined sample still showed marked statistical trends regarding an association. The sex distribution in the Ͻ1.0 and Ͻ1.5 SD subgroups was not statistically different from the total sample (across both samples: no criterion: 44.3%, 1.0 SD: 48.3%, 1.5 SD: 43.9% females). Thus, this effect could not be attributed to an accumulation of females in the low PPI subgroups.
There was no significant association of TCF4 rs9960767 genotype with a diagnosis of schizophrenia (Armitage trend test for the TCF4 C-allele: common odds ratio ϭ 0.71, 2 ϭ 0.92; p ϭ 0.34). However, given that the sample size was rather small and possible effects of population stratification, this result should be interpreted with caution.
Discussion
The present study is the first to investigate the influence of the schizophrenia risk gene TCF4 rs9960767 on an established endophenotype of schizophrenia. In two independent samples, we could convincingly demonstrate that the schizophrenia risk allele C of the TCF4 rs9960767 SNP is strongly associated with reduced sensorimotor gating. In a meta-analysis of the largest genomewide association study to date, consisting of 12,945 schizophrenia cases and 34,591 controls, this TCF4 SNP was among the most statistically significant findings (Stefansson et al., 2009 ). The possible role of TCF4 genes in the development of schizophrenia was lately confirmed in a large sample of Han Chinese, in which a neighboring SNP was shown to have an impact on schizophrenia risk (Li et al., 2010) . In accordance with recent animal data, showing that transgenic mice overexpressing the TCF4 gene in the brain display decreased sensorimotor gating (Brzó zka et al., 2010) , this finding suggests that TCF4 plays an important role in the development of early information deficits in schizophrenia at least in a subgroup of patients who display diminished PPI.
The role of TCF4 (also known as E2-2, SEF-2, ME-2, or ITF-2) in the brain and the functional activity of the investigated TCF4 variant on the level of gene expression are not fully understood Figure 1 . The effects of TCF4 rs9960767 genotype on percentage PPI of the acoustic startle response (means and SEM, adjusted for sex and smoking) in 98 British healthy human volunteers (ANCOVA corrected for sex and smoking: ***p Ͻ 0.001; A) and in a combined sample of 68 schizophrenia patients and 37 individuals at high risk for schizophrenia from Germany (ANCOVA corrected for sex, smoking, and antipsychotic medication: *p Ͻ 0.05; B). SOA30, SOA60, and SOA120, Stimulus onset asynchrony of 30, 60, and 120 ms, respectively, between prepulse and pulse alone.
yet, but bHLH transcription factors such as TCF4 seem to play an important role in the development of the mammalian cortex as neuronal progenitors (Ross et al., 2003; Flora et al., 2007) . TCF4 belongs to a subfamily of bHLH transcriptional regulators that recognizes the Ephrussi-box ("E-box") binding site on the DNA that usually lies upstream of a gene in a promoter region (Zweier et al., 2007) . At early developmental stages, E-box transcription factors such as TCFE2a, TCF12, and TCF4 show wide expression throughout the brain, but only TCF4 displays sustained expression in the adult brain of mice, which is most prominent in the cerebellum, hippocampus, and cortex (Soosaar et al., 1994; Uittenbogaard and Chiaramello, 2000; Brzó zka et al., 2010) .
TCF4-null knock-out mice die in the first 24 h after birth (Zhuang et al., 1996; Flora et al., 2007) , and haploinsufficiency of the TCF4 gene in humans causes the Pitt-Hopkins syndrome (Zweier et al., 2007; de Pontual et al., 2009 )-a neurodevelopmental disease characterized by severe mental retardation, microcephaly, epilepsy, facial dysmorphisms, and intermittent hyperventilation, suggesting that TCF4 is critical for the development of the mammalian nervous system. It was recently shown in TCF4 knock-out mice that TCF4 plays a unique role especially in the development of the pontine nuclei (Flora et al., 2007) . These nuclei are highly interconnected with the pedunculopontine and laterodorsal tegmental nuclei, the caudal pontine reticular nucleus, and the superior colliculus (Vertes et al., 1986; Redgrave et al., 1987; Woolf and Butcher, 1989) , which are critical core regions within the CSPP circuitry processing PPI of ASR (Koch, 1999; Fendt et al., 2001; Swerdlow et al., 2001) . Although the influence of pontine nuclei on PPI has not been studied so far, one might speculate that developmental changes in these nuclei caused by TCF4 mutations are possibly associated with functional alterations of connections to neighboring brainstem nuclei as well as of the cortico-ponto-cerebellar integration of sensorimotor information. This assumption is also supported by the fact that, in the London sample, PPI was strongly affected by TCF4 genotype across the entire range of SOA conditions-from the "preconscious" 30 ms SOA to the "conscious" 120 SOA. This pattern suggests that TCF4 genotype probably influences PPI at an early level of information processing. The role of TCF4 in sensorimotor gating could be further investigated by studying PPI in patients with Pitt-Hopkins syndrome (Zweier et al., 2007) . However, this mutation is rare and the recruitment of a sufficient sample size as well as the matching would be a demanding exercise.
In the meantime, numerous association studies in healthy humans and schizophrenia patients suggest that PPI is influenced by several genetic variations. It was shown that SNPs of the serotonin-2A receptor Hedges and Olkin (1985) .
al. , 2008a,b; Petrovsky et al., 2010) , which parallels well the neural circuitry that underlies and supports PPI of the ASR (Swerdlow and Koob, 1987; Koch, 1999; Fendt et al., 2001; Swerdlow et al., 2001) . Thus, it is most likely that each of these genetic polymorphisms contributes a small fraction to the variant expression of PPI in the population. If PPI is an appropriate endophenotype of schizophrenia, as has been proposed, a combination of these SNPs might also contribute to the risk for schizophrenia. Nevertheless, it is not known at present whether and how these SNPs may interact with regard to sensorimotor gating, as the sample sizes investigated so far (Ͻ250 subjects) were not suitable to investigate the interactive and epistatic effects even of two SNPs with moderate minor allele frequencies. Further studies with larger sample sizes (Ͼ500) are needed to reliably examine these effects. However, since very few schizophrenia patients seem to share identical genomic causation (Need et al., 2009) , reduced PPI most likely also arises from several independent genetic variations. In our samples, schizophrenia was not associated with TCF4 genotype, as was previously shown (Stefansson et al., 2009) . However, our sample sizes were too small and had power too low to detect common, relatively low-risk variants such as TCF4, which shows a mean odds ratio of 1.23 (confidence interval: 1.15-1.32) in a large meta-analysis (Stefansson et al., 2009) . Moreover, the two samples were recruited in different European countries, limiting the direct comparability because of possible population stratification effects, which were not statistically controlled by a standard panel of ancestry-informative SNPs. However, the investigation of the association of TCF4 and schizophrenia was not the focus of the present study. Interestingly, low PPI levels have shown stronger associations with the TCF4 risk allele C than schizophrenia per se: depending on the criterion for decreased PPI (1 or 1.5 SD below normal), odds ratios of 2.38 and 4.81 were calculated for the entire sample (Table 4) . When considering the effect size measures according to Cohen (1988) , a similar pattern arises: In the meta-analysis, the association of a diagnosis of schizophrenia with TCF4 genotype displayed only a very small effect size of w ϭ 0.09 (Stefansson et al., 2009) . In contrast, the association of the schizophrenia endophenotype PPI with TCF4 showed a strong effect size of d ϭ 0.90 averaged across both samples. Thus, the endophenotype approach could boost the power of a genetic study compared with the approach of classical categorization of the mental illness using the current diagnostic manuals. Furthermore, given that TCF4 genotype was significantly associated with PPI reduction, a combination of TCF4 genotype status and low PPI levels might be a promising marker for the early detection of schizophrenia.
The study has some limitations. (I) The total size of our samples seems to be modest. However, compared to other studies in the field, our study with a sample size of n ϭ 203 still belongs to the best-powered PPI genetics studies. In contrast to many other association studies, we recruited a highly homogeneous sample regarding ethnicity because we only included Caucasians from Middle Europe with self-reported grandparents of Middle European origin. Thus, we have a modest but clear and well selected sample, which might be preferable compared to ethnically mixed but larger samples.
(II) Are the sample sizes of subjects carrying the C-allele too low for a reliable estimation of the group PPI levels? We do not assume this for three reasons: (1) We tested two independent samples as we aimed to obtain an internal replication of our results especially to avoid spurious results. The replication of the initial results in an independent sample makes it statistically highly unlikely that both results could be accidental or spurious.
(2) To estimate the strength of the results, we conducted several meta-analyses with different approaches (Table 3) . They all revealed a very strong genotype effect of the investigated TCF4 SNP on PPI across both samples ( p Ͻ 0.0001-0.00002, mean Cohen's d ϭ 0.90), which is the strongest genotype effect on PPI that has been shown across more than one tested sample so far. (3) In total, we have 23 subjects carrying the C-allele, which is sufficient for a reliable estimation of the mean PPI of a group. Of these 23 subjects, 14 (61%) displayed decreased PPI levels, when compared to the total sample (Table 4) , which is again an expression of the strong genotype effect of TCF4 on PPI. Moreover, most of the positive results of previous genetic PPI studies are based on comparable or smaller SNP subgroups (e.g., Hong et al., 2008; Quednow et al., 2008b Quednow et al., , 2009 Quednow et al., , 2010 Roussos et al., 2008a,b) . Thus, compared to the field of PPI genetics (as well as compared to many clinical PPI studies), a total of 23 risk allele carriers should be sufficient for a reliable and valid estimation of the mean PPI levels.
(III) The two independent samples were assessed with slightly different PPI paradigms, which preclude the direct comparison of the samples regarding PPI. Therefore, we decided to analyze the genotype effects only within each sample and to subsequently pool the p values and effect sizes of the genotype effects in metaanalyses to overcome these methodological differences. The replication of the genotype effects within each of the samples and across study sites despite some procedural differences underscores the robustness of our findings.
(IV) All participants were screened for drug use within the SCID-I interview, but we only obtained drug urine toxicologies from our schizophrenia patients to rule out current drug use. Thus, we could exclude acute illicit drug effects on PPI only in a subset of the total subjects. However, given the strict inclusion criteria, it is highly unlikely that a significant number of subjects would have been taking drugs, and even less likely that a gene- The healthy London sample refers to itself (mean PPI across 30 ms, 60 ms, and 120 ms SOA conditions: 30.8 Ϯ 17.2% SD), whereas the schizophrenia spectrum Bonn sample refers to a normal population showing a mean PPI of 58.1% (Ϯ21.7 SD) at an SOA of 120 ms measured with the same setup (Quednow et al., 2008a) .
b
Fisher's exact test.
phenotype association that is observed in two independent samples could be accounted for by this.
(V) Finally, estimations of the genetic effect based on novel association findings tend to be upwardly biased due to a phenomenon also known as the "winner's curse" (Xiao and Boehnke, 2009) . However, given that we replicated our finding in a second sample and considering the fact that the effect size of TCF4 genotype effect seems to be one of the strongest genotype effects on PPI reported so far (e.g., Quednow et al., 2008b Quednow et al., , 2009 Quednow et al., , 2010 Roussos et al., 2008a Roussos et al., ,b, 2009 Petrovsky et al., 2010) , it is highly likely that this effect will survive further investigation.
In conclusion, our results suggest that TCF4 variants could play an important role in the development of diminished sensorimotor gating in schizophrenia. These deficits might arise from developmental changes of brainstem nuclei. As subjects carrying the TCF4 rs9960767 C-allele robustly showed diminished PPI levels, an extended endophenotype including PPI and TCF4 genotype status warrants testing as an early indicator for a developing psychosis (Prasad and Keshavan, 2008) .
